Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?.
Angiology. 60(4), 397-402.
(2009). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention..
Curr Med Res Opin. 30(1), 55.
(2014). The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia..
Curr Med Chem. 27(39), 6682-6702.
(2020). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis..
Metab Syndr Relat Disord. 8(6), 523-9.
(2010). Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia..
Curr Pharm Des. 24(46), 5542-5547.
(2018). Carbon dioxide balneotherapy and cardiovascular disease..
Int J Biometeorol. 55(5), 657-63.
(2011). Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?.
Angiology. 60(1), 74-81.
(2009). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Cardiovascular Risk in Middle East Populations: A Call to Action..
Angiology. 66(9), 801-2.
(2015). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review..
Angiology. 65(4), 284-93.
(2014). Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis..
J Clin Endocrinol Metab. 94(8), 2692-701.
(2009). Cold temperature and cardiovascular mortality..
Circ J. 77(11), 2846.
(2013). Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease..
Expert Opin Ther Targets. 17(7), 861-2.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study..
Open Cardiovasc Med J. 8, 55-60.
(2014). Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD..
J Clin Hypertens (Greenwich).
(2020). Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population..
Curr Med Res Opin. 26(3), 713-9.
(2010). A comparison of the aldosterone-blocking agents eplerenone and spironolactone..
Clin Cardiol. 32(4), 230.
(2009).